Never miss an issue of Master Investor Magazine – sign-up now for free!
AIM-listed neuroscientific data specialist IXICO (LON:IXI) announced that revenues for the year ended 30th September rose by 32% to £5.4 million as it expanded the medical imaging services it offers to pharmaceutical clients and began earning revenues from its wearable biosensor projects. Total income for the year rose by 25%.
Management also said that the firm had signed several new multi-year contracts that would earn a combined £15 million, which they believe provides a foundation for future growth. Full results for the year will be published in early December.
Shares in IXICO climbed by 10.44% to 31.20p (as of 13:20 BST).